Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Dinutuximab Approved for High-Risk Neuroblastoma
Home
Publications
Dinutuximab Approved for High-Risk Neuroblastoma
Dinutuximab Approved for High-Risk Neuroblastoma
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Open Access
Publisher website
Google Scholar
1 June 2015
journal article
other
Published by
American Association for Cancer Research (AACR)
in
Cancer Discovery
Vol. 5
(6)
,
OF5
DOI:
10.1158/2159-8290.cd-nb2015-044
PMID:
25851859
Abstract
The FDA approved the use of dinutuximab, in combination with three other agents, for high-risk neuroblastoma, offering patients the first major new treatment in more than a decade.
Keywords
HIGH-RISK NEUROBLASTOMA
FDA APPROVED
OFFERING PATIENTS
DINUTUXIMAB APPROVED
NEUROBLASTOMA
HIGH-RISK
APPROVED
FDA
AGENTS
OFFERING
Related articles
Cited
Cited by 11 articles
Scroll to top